[2] [3] [4] [5] A separate product, semaglutide subcutaneous injection, is indicated as an adjunct to lifestyle modifications for weight loss and chronic weight management in obese (BMI 30 kg/m2 or greater) or overweight adults (BMI 27 kg/m2 or greater) with at least 1 weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
The argument is that peptides encourage the body to carry out processes it already has pathways for such as secreting growth hormone, regulating cortisol, or improving circulation rather than introducing entirely foreign chemistry
Sue Decotiis, who is based in New York, confirmed in an interview with Fox News Digital how patients have experienced an improvement in various conditions while on these medications
They are not intended for use in or on humans or animals under any circumstances
Supports improvements for gastric ulcers, IBS, leaky gut, Crohns disease, and other GI issues